Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx
Rhea-AI Summary
Ardelyx (Nasdaq: ARDX) announced the appointment of Rajani Dinavahi, MD as Chief Medical Officer effective April 1, 2026. Dr. Dinavahi brings more than two decades of clinical and development experience across immuno-oncology, autoimmune, metabolic disease, nephrology and transplantation.
Her background includes senior leadership at Atara Biotherapeutics and prior roles at Amgen, with experience advancing programs from early development through Phase 3 and regulatory approval.
Positive
- Appointment effective April 1, 2026
- 20+ years of clinical and biotech experience
- Led global development for an approved allogeneic T-cell therapy
- Broad therapeutic expertise: immuno-oncology, autoimmune, metabolic, nephrology, transplantation
- Senior leadership experience at Atara and program work at Amgen
Negative
- None.
News Market Reaction – ARDX
In the Apr 1 session, ARDX gained 2.00%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 12 | Patient advocacy award | Positive | -5.5% | Recognition of five chronic kidney disease advocates with company-sponsored award. |
| Mar 09 | Clinical review data | Positive | -0.8% | Peer‑reviewed analysis showing rapid, sustained IBS‑C symptom relief with tenapanor. |
| Mar 04 | Investor conferences | Positive | +6.9% | Planned presentations and 1x1 meetings at major Miami healthcare investor events. |
| Feb 24 | LPGA partnership | Positive | +14.1% | Multi‑year LPGA collaboration to raise awareness of IBS‑C and digestive health. |
| Feb 19 | Earnings and guidance | Positive | -15.0% | 2025 results, strong IBSRELA and XPHOZAH sales, 2026 revenue guidance and net loss. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent ARDX news has often seen outsized moves, with several positive updates met by both sharp gains and notable selloffs, indicating volatile and sometimes contrarian reactions to announcements.
Over the past months, Ardelyx has reported strong business progress, including $407.3M in 2025 revenue, with IBSRELA at $274.2M and XPHOZAH at $103.6M, plus 2026 revenue guidance for both products. The stock reacted -14.99% to that earnings update. By contrast, a multi‑year LPGA partnership saw a 14.09% gain, and investor‑conference participation lifted shares 6.91%. Other positive scientific and patient‑advocacy news produced modest to negative moves, underscoring uneven market responses. Today’s CMO appointment fits the pattern of strategically focused, non-clinical catalysts.
Key Terms
immuno-oncology medical
nephrology medical
allogeneic T-cell therapy medical
T-cell directed therapy medical
translational immunology medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced the appointment of Rajani Dinavahi, MD, as Chief Medical Officer (CMO). Dr. Dinavahi brings more than two decades of experience in healthcare and biotechnology, spanning multiple therapeutic areas and modalities. She has extensive experience across immuno-oncology, autoimmune diseases, metabolic disease, nephrology and transplantation, with a track record of advancing programs from early development through Phase 3 and regulatory approval. Dr. Dinavahi most recently served as Senior Vice President, Chief Medical Officer at Atara Biotherapeutics.
“I am delighted to welcome Rajani as our new Chief Medical Officer. She brings a rare combination of scientific rigor, clinical expertise and proven leadership in advancing innovative therapies from development to patients,” said Mike Raab, president and chief executive officer of Ardelyx. “As we enter an important phase of growth and execution, Rajani’s experience and vision will be instrumental in strengthening our pipeline, deepening our medical capabilities, and ensuring we continue to deliver meaningful outcomes for patients. I look forward to partnering closely with her as we build on our momentum and shape the next chapter of our company.”
“I am thrilled to join Ardelyx at such a pivotal time in its evolution,” said Dr. Dinavahi. “The company’s commitment to advancing innovative therapies and its focus on patients strongly align with my own values and experience. I’ve been deeply impressed by the strength of the science, the dedication of the team and the opportunity to meaningfully impact patients’ lives. I look forward to working alongside this talented organization to advance the pipeline, build on the company’s momentum and help deliver important new medicines to patients who need them.”
As Chief Medical Officer at Atara Biotherapeutics, Dr. Dinavahi’s responsibilities spanned leading pre-clinical and translational sciences through global development and medical affairs of their lead T-cell directed therapy asset and allo-CART program. Prior to becoming CMO, Dr. Dinavahi held senior leadership positions at Atara across clinical sciences, program team leadership and medical affairs, where she built and led global teams to deliver on the first allogeneic T-cell therapy to be approved and launched globally. Earlier, she spent seven years at Amgen, contributing to multiple global development programs and regulatory filings for products approved across the U.S., Europe and Japan.
Dr. Dinavahi began her career in academic medicine as an Assistant Professor of Medicine (Nephrology) at Mount Sinai School of Medicine and a principal investigator in transplant research. She is board-certified in Internal Medicine and Nephrology, a Fellow of the American Society of Nephrology, and has authored numerous scientific publications and presentations. She earned a Bachelor of Science and Doctor of Medicine from the University of Miami and completed her Internal Medicine residency and Nephrology fellowship training at Thomas Jefferson University Hospital, followed by a clinical transplant and post-doctoral fellowship focusing on translational immunology at Mount Sinai Hospital in New York City.
About Ardelyx
Ardelyx is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). The company’s pipeline includes the Phase 3 development of tenapanor for chronic idiopathic constipation, and RDX10531, a next-generation NHE3 inhibitor with potential application across multiple therapeutic areas. Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.
Investor Contact:
Lisa Caperelli
lcaperelli@ardelyx.com
